Benzinga’s “Daily Brief On Trending Tickers” highlights top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news items possibly impacting those stocks.
Yumanity Therapeutics, Inc. to sell its clinical-stage product candidate YTX-7739 as well as its unpartnered discovery-stage neuroscience product candidates and targets to Janssen Pharmaceutica NV in a $26 million cash
Gainers
Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares climbed 118.4% to close at $74.59 on Friday after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per share.
Benzinga Pro data, Yumanity Therapeutics (NASDAQ:YMTX) reported Q4 sales of $762.00 thousand. Earnings fell to a loss of $10.41 million, resulting in a 4.57% decrease from last quarter.
Gainers
Forge Global Holdings Inc. (NYSE: FRGE) shares jumped 67.7% to $16.95. True Global Ventures’ portfolio company Forge Global Holdings completed its business combination with Motive Capital Corp on the 22nd of March, 2022.